Premium
A phase II study of triazinate (NSC 139105) in advanced colorectal carcinoma
Author(s) -
McCreary Robert H.,
Moertel Charles G.,
Schutt Alan J.,
O'Connell Michael J.,
Hahn Richard G.,
Reitemeier Richard J.,
Rubin Joseph,
Frytak Stephen
Publication year - 1977
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197707)40:1<9::aid-cncr2820400104>3.0.co;2-6
Subject(s) - medicine , colorectal cancer , oncology , carcinoma , cancer
Triazinate (Baker's Antifol, NSC 139105) was given to 28 patients as a single agent in the chemotherapy of advanced colerectal carcinoma. The dosage utilized was 250 mg/m 2 intravenously, administered daily in three consecutive days. Patients were evaluated at three weeks, six weeks, and then monthly until progression was evident. Various immunologic determinants (i.e., DNCB sensitization, immunoglobulins, recall skin tests, lymphocyte blastogenesis, and circulating lymphocytes, T‐cells and B‐cells) were obtained prior to treatment and at each re‐evaluation. The principal side effects were dermatitis, stomatitis, diarrhea, nausea, somnolence, and leukopenia. There was no discernable effect of Triazinate on the immunologic determinants tested. There was one complete response, and four partial responses, for an objective regression rate of 18%. This study suggests that Triazinate has a definite, though limited, effect on advanced colorectal carcinoma. Cancer 40:9–13, 1977.